{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:17:04Z","timestamp":1763018224760,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T00:00:00Z","timestamp":1597449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00277-020-04212-1","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T11:02:42Z","timestamp":1597489362000},"page":"2393-2404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-4459","authenticated-orcid":false,"given":"Takayoshi","family":"Tachibana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaito","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On Behalf of the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,15]]},"reference":[{"key":"4212_CR1","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.leu.2402526","volume":"16","author":"J Takeuchi","year":"2002","unstructured":"Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R (2002) Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 16:1259\u20131266","journal-title":"Leukemia"},{"key":"4212_CR2","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","volume":"99","author":"B Glei\u00dfner","year":"2002","unstructured":"Glei\u00dfner B, Gokbuget N, Bartram CR et al (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99:1536\u20131543","journal-title":"Blood"},{"key":"4212_CR3","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","volume":"100","author":"H Dombret","year":"2002","unstructured":"Dombret H, Gabert J, Boiron J-M, Rigal-Huguet F, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Nabera C, Cayuela JM, Fenaux P, Bourhis JH, Fegueux N, Charrin C, Boucheix C, Lh\u00e9ritier V, Esp\u00e9rou H, MacIntyre E, Vernant JP, Fi\u00e8re D, Groupe d'Etude et de Traitement de la Leuc\u00e9mie Aigu\u00eb Lymphoblastique de l'Adulte (GET-LALA Group) (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial. Blood 100:2357\u20132366","journal-title":"Blood"},{"key":"4212_CR4","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","volume":"111","author":"V Pullarkat","year":"2008","unstructured":"Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR (2008) Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood 111:2563\u20132572","journal-title":"Blood"},{"key":"4212_CR5","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, Marks DI, McMillan A, Litzow MR, Lazarus HM, Foroni L, Dewald G, Franklin IM, Luger SM, Paietta E, Wiernik PH, Tallman MS, Goldstone AH (2009) Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993. Blood 113:4489\u20134496","journal-title":"Blood"},{"key":"4212_CR6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group (2006) High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24:460\u2013466","journal-title":"J Clin Oncol"},{"key":"4212_CR7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/leu.2010.228","volume":"25","author":"S Mizuta","year":"2011","unstructured":"Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Miyazaki Y, Ohtake S, Atsuta Y, Sakamaki H, Kawa K, Morishima Y, Ohnishi K, Naoe T, Ohno R (2011) Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR\u2013ABL-positive acute lymphoblastic leukemia. Leukemia 25:41\u201347","journal-title":"Leukemia"},{"key":"4212_CR8","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H (2004) Treatment of Philadelphia chromosome\u2013positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 103:4396\u20134407","journal-title":"Blood"},{"key":"4212_CR9","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","volume":"108","author":"B Wassmann","year":"2006","unstructured":"Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornh\u00e4user M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Br\u00fcck P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG (2006) Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 108:1469\u20131477","journal-title":"Blood"},{"key":"4212_CR10","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","volume":"109","author":"A de Labarthe","year":"2007","unstructured":"de Labarthe A, Rousselot P, Huguet-Rigal F et al (2007) Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109:1408\u20131413","journal-title":"Blood"},{"key":"4212_CR11","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/cncr.22631","volume":"109","author":"OG Ottmann","year":"2007","unstructured":"Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, D\u00fchrsen U, Schmalzing M, Wunderle L, Binckebanck A, Hoelzer D, for the GMALL Study Group (2007) Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 109:2068\u20132076","journal-title":"Cancer"},{"key":"4212_CR12","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, Martinelli G, di Raimondo F, Ferrara F, Meloni G, Ambrosetti A, Quarta G, Pagano L, Rege-Cambrin G, Elia L, Bertieri R, Annino L, Fo\u00e0 R, Baccarani M, Mandelli F (2007) Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia patients without additional chemotherapy: results of the GIMEMA LAL0201-B protocol. Blood 109:3676\u20133678","journal-title":"Blood"},{"key":"4212_CR13","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","volume":"118","author":"R Fo\u00e0","year":"2011","unstructured":"Fo\u00e0 R, Vitale A, Vignetti M, Meloni G, Guarini A, de Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, Soverini S, Mandelli F, Martinelli G, Baccarani M, on behalf of the GIMEMA Acute Leukemia Working Party (2011) Dasatinib as first-line treatment for adult patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. Blood 118:6521\u20136528","journal-title":"Blood"},{"key":"4212_CR14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot P, Coud\u00e9 MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG, European Working Group on Adult ALL (EWALL) group (2016) Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 128:774\u2013782","journal-title":"Blood"},{"key":"4212_CR15","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H (2010) First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116:2070\u20132077","journal-title":"Blood"},{"key":"4212_CR16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/annonc\/mdw123","volume":"27","author":"JH Yoon","year":"2016","unstructured":"Yoon JH, Yhim HY, Kwak et al (2016) Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Oncol 27:1081\u20131088","journal-title":"Ann Oncol"},{"key":"4212_CR17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, M\u00fcller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM (2018) Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132:393\u2013404","journal-title":"Blood"},{"key":"4212_CR18","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo D, Abruzzese E, Rea D, Baccarani M, M\u00fcller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H, PACE Investigators (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783\u20131796","journal-title":"N Engl J Med"},{"key":"4212_CR19","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","volume":"5","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H (2018) Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5:e618\u2013e627","journal-title":"Lancet Haematol"},{"key":"4212_CR20","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","volume":"122","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM (2016) Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer 122:3650\u20133656","journal-title":"Cancer"},{"key":"4212_CR21","unstructured":"Hematopoietic Cell Transplantation in Japan. Annual Report of Nationwide Survey 2018 (2018) The Japanese Data Center for Hematopoietic Cell Transplantation\/The Japan Society for Hematopoietic Cell Transplantation"},{"key":"4212_CR22","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"S Soverini","year":"2014","unstructured":"Soverini S, De Benedittis C, Papayannidis C et al (2014) Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer 120:1002\u20131009","journal-title":"Cancer"},{"key":"4212_CR23","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3109\/10428194.2016.1144881","volume":"57","author":"R DeBoer","year":"2016","unstructured":"DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W (2016) Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma 57:2298\u20132306","journal-title":"Leuk Lymphoma"},{"key":"4212_CR24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.leukres.2010.12.006","volume":"35","author":"T Ono","year":"2011","unstructured":"Ono T, Miyawaki S, Kimura F, Kanamori H, Ohtake S, Kitamura K, Fujita H, Sugiura I, Usuki K, Emi N, Tamaki S, Aoyama Y, Kaya H, Naoe T, Tadokoro K, Yamaguchi T, Ohno R, Ohnishi K, Japan Adult Leukemia Study Group (2011) BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Leuk Res 35:598\u2013603","journal-title":"Leuk Res"},{"key":"4212_CR25","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2011-07-367326","volume":"118","author":"FE Nicolini","year":"2011","unstructured":"Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, M\u00fcller MC, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Labussi\u00e8re H, Morisset S, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J (2011) Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 118:5697\u20135700","journal-title":"Blood"},{"key":"4212_CR26","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","volume":"123","author":"FE Nicolini","year":"2017","unstructured":"Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE (2017) Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer 123:2875\u20132880","journal-title":"Cancer"},{"key":"4212_CR27","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","volume":"109","author":"A Ray","year":"2007","unstructured":"Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD (2007) Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109:5011\u20135015","journal-title":"Blood"},{"key":"4212_CR28","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640\u20132653","journal-title":"Blood"},{"key":"4212_CR29","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15:1628\u20131633","journal-title":"Biol Blood Marrow Transplant"},{"key":"4212_CR30","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825\u2013828","journal-title":"Bone Marrow Transplant"},{"key":"4212_CR31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Donnall Thomas E (1980) Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204\u2013217","journal-title":"Am J Med"},{"key":"4212_CR32","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"4212_CR33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ajh.22272","volume":"87","author":"M Alikian","year":"2012","unstructured":"Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, Rezvani K, Goldman J, Apperley J, Foroni L (2012) BCR-ABL1 kinase domain mutations: methodology and clinical evaluation. Am J Hematol 87:298\u2013304","journal-title":"Am J Hematol"},{"key":"4212_CR34","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood-2018-99-117166","volume":"132","author":"S Soverini","year":"2018","unstructured":"Soverini S, Bavaro L, Martelli M, de Benedittis C, Iurlo A, Orofino N, Pagano L, Criscuolo M, Bonifacio M, Scaffidi L, Sica S, Sor\u00e0 F, Maino E, Rondoni M, Laginestra MA, Lunghi F, Ermacora A, D'adda M, Gugliotta G, Castagnetti F, Rosti G, Papayannidis C, Marconi G, Curti A, Miggiano MC, Galimberti S, Percesepe A, Stagno F, Sancetta R, Annunziata M, Falzetti F, Capodanno I, Pregno P, Maffioli M, Intermesoli T, di Bona E, Caocci G, Attolico I, Binotto G, Bocchia M, Angelucci E, Sgherza N, Luciano L, Mignone F, Pileri SA, Martinelli G, Cavo M (2018) Compound BCR-ABL1 kinase domain mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a prospective series of Philadelphia chromosome-positive leukemia patients analyzed by next generation sequencing. Blood 132:789","journal-title":"Blood"},{"key":"4212_CR35","first-page":"1779","volume":"32","author":"K Watanabe","year":"2012","unstructured":"Watanabe K, Minami Y, Ozawa Y, Miyamura K, Naoe T (2012) T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports. Anticancer Res 32:1779\u20131783","journal-title":"Anticancer Res"},{"key":"4212_CR36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12185-018-02571-0","volume":"109","author":"T Tachibana","year":"2019","unstructured":"Tachibana T, Koyama S, Andou T, Ishiyama Y, Tanaka M, Nakajima H, Kanamori H (2019) Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia. Int J Hematol 109:162\u2013168","journal-title":"Int J Hematol"},{"key":"4212_CR37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M et al (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375:740\u2013753","journal-title":"N Engl J Med"},{"key":"4212_CR38","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Topp MS, Fielding AK, Rambaldi A, Ritchie EK, Papayannidis C, Sterling LR, Benjamin J, Stein A (2017) Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 35:1795\u20131802","journal-title":"J Clin Oncol"},{"key":"4212_CR39","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509\u20131518","journal-title":"N Engl J Med"},{"key":"4212_CR40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fonc.2019.00088","volume":"9","author":"R Krishna Chandran","year":"2019","unstructured":"Krishna Chandran R, Geetha N, Sakthivel KM, Suresh Kumar R, Jagathnath Krishna KMN, Sreedharan H (2019) Impact of Additional chromosomal aberrations on the disease progression of chronic myelogenous leukemia. Front Oncol 9:88","journal-title":"Front Oncol"},{"key":"4212_CR41","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","volume":"27","author":"W Wang","year":"2016","unstructured":"Wang W, Cortes JE, Tang G et al (2016) Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 27:2742\u20132750","journal-title":"Blood"},{"key":"4212_CR42","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/j.bbmt.2018.06.006","volume":"24","author":"Y Akahoshi","year":"2018","unstructured":"Akahoshi Y, Mizuta S, Shimizu H, Uchida N, Fukuda T, Kanamori H, Onizuka M, Ozawa Y, Ohashi K, Ohta S, Eto T, Tanaka J, Atsuta Y, Kako S, Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (2018) Additional cytogenetic abnormalities with Philadelphia chromosome-positive acute lymphoblastic leukemia on allogeneic stem cell transplantation in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant 24:2009\u20132016","journal-title":"Biol Blood Marrow Transplant"},{"key":"4212_CR43","unstructured":"Ottmann OG, Pfeifer H (2009) Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology Am Soc Hematol Educ Program:371\u2013381"},{"key":"4212_CR44","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.bbmt.2016.07.021","volume":"22","author":"F Lussana","year":"2016","unstructured":"Lussana F, Intermesoli T, Gianni F, Boschini C, Masciulli A, Spinelli O, Oldani E, Tosi M, Grassi A, Parolini M, Audisio E, Cattaneo C, Raimondi R, Angelucci E, Cavattoni IM, Scattolin AM, Cortelezzi A, Mannelli F, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Romani C, Bassan R, Rambaldi A (2016) Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact on relapse and long-term outcome. Biol Blood Marrow Transplant 22:1983\u20131987","journal-title":"Biol Blood Marrow Transplant"},{"key":"4212_CR45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bmt.2015.217","volume":"51","author":"S Nishiwaki","year":"2016","unstructured":"Nishiwaki S, Imai K, Mizuta S et al (2016) Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant 51:43\u201350","journal-title":"Bone Marrow Transplant"},{"key":"4212_CR46","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjh.12970","volume":"166","author":"L Tucunduva","year":"2014","unstructured":"Tucunduva L, Ruggeri A, Sanz G, Furst S, Cornelissen J, Linkesch W, Mannone L, Ribera JM, Veelken H, Yakoub-Agha I, Gonz\u00e1lez Valent\u00edn ME, Schots R, Arcese W, Montesinos P, Labopin M, Gluckman E, Mohty M, Rocha V (2014) Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation. Br J Haematol 166:749\u2013757","journal-title":"Br J Haematol"},{"key":"4212_CR47","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"S Giebel","year":"2016","unstructured":"Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, Cornelissen JJ, Esteve J, Gorin NC, Savani B, Schmid C, Mohty M, Nagler A (2016) Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer 122:2941\u20132951","journal-title":"Cancer"},{"key":"4212_CR48","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.clml.2016.04.017","volume":"16","author":"Z DeFilipp","year":"2016","unstructured":"DeFilipp Z, Langston AA, Chen Z, Zhang C, Arellano ML, el Rassi F, Flowers CR, Kota VK, al-Kadhimi Z, Veldman R, Jillella AP, Lonial S, Waller EK, Khoury HJ (2016) Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia? Clin Lymphoma Myeloma Leuk 16:466\u2013471","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4212_CR49","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","volume":"27","author":"H Pfeifer","year":"2013","unstructured":"Pfeifer H, Wassmann B, Bethge W et al (2013) Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia 27:1254\u20131262","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04212-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04212-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04212-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T23:14:26Z","timestamp":1628982866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04212-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["4212"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04212-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,8,15]]},"assertion":[{"value":"3 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.S. reports personal fees from Chugai, personal fees from Pfizer, personal fees from Astellas, personal fees from Nippon-Shinyaku, personal fees from Ono, personal fees from MSD, personal fees from Bristol-Myers Squibb, personal fees from Kyowa-Hakko Kirin, personal fees from Asahi-Kasei, personal fees from Novartis, personal fees from Eisai, personal fees from Otsuka, personal fees from Sumitomo Dainippon, personal fees from Sanofi, personal fees from Takeda, personal fees from Celgene, personal fees from Mochida, personal fees from Shire, personal fees from Mundipharma, outside the submitted work. S. H. reports stock ownership in Revorf Co.,ltd. outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the data management committee of the Japanese Society for Hematopoietic Cell Transplantation and the Ethics Committee of Kanagawa Cancer Center. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The TRUMP database includes physician-reviewed data. Observational studies based on the TRUMP database are performed with an informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}